There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.Įmail: of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. The RSUs and any underlying common shares in the capital of the Company will be subject to a four month and one day hold period pursuant to the policies of the Canadian Securities Exchange. The RSUs will vest in 25% intervals, every 6 months from the date of the grant. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that it has granted an aggregate of 325,000 restricted share units ("RSUs") effective March 11, 2022, to certain executives and employees of the Company pursuant to its restricted share unit plan. TORONTO, ON / ACCESSWIRE / Ma/ Novamind Inc. Any failure to comply with this restriction may constitute a violation of U.S.
Newswire Services or for dissemination in the United States.